Compare CABA & CCRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABA | CCRN |
|---|---|---|
| Founded | 2017 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.6M | 270.9M |
| IPO Year | 2019 | 2001 |
| Metric | CABA | CCRN |
|---|---|---|
| Price | $2.94 | $8.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $14.57 | $13.15 |
| AVG Volume (30 Days) | ★ 2.3M | 555.2K |
| Earning Date | 03-16-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $816,484,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.35 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.99 | $7.43 |
| 52 Week High | $3.78 | $15.30 |
| Indicator | CABA | CCRN |
|---|---|---|
| Relative Strength Index (RSI) | 46.38 | 44.49 |
| Support Level | $2.11 | $7.68 |
| Resistance Level | $3.34 | $9.40 |
| Average True Range (ATR) | 0.21 | 0.46 |
| MACD | -0.06 | -0.06 |
| Stochastic Oscillator | 18.33 | 16.18 |
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
Cross Country Healthcare Inc is a provider of total talent management services, including strategic workforce solutions, contingent staffing, permanent placement and consultative services for healthcare customers. The company operates in two business segments: the nurse and allied staffing segment, which generates a vast majority of revenue, offers temporary and permanent placements of travel and local nurses and allied professionals, and other outsourcing services.: the Physician Staffing segment provides licensed practitioners across a broad array of specialties, as well as certified registered nurse anesthetists (CRNAs), nurse practitioners (NPs), and physician assistants (PAs) on temporary assignments. The company earns majority of its revenue from the United States.